Roche's Lunsumio-Lenalidomide Combo Hits Primary Endpoint in Phase III CELESTIMO Follicular Lymphoma Trial
核心洞察
Genentech reported that Lunsumio plus lenalidomide significantly improved progression-free survival versus rituximab plus lenalidomide in relapsed or refractory follicular lymphoma (搜索).
The Phase III CELESTIMO trial met its primary endpoint at interim analysis, showing a statistically significant and clinically meaningful reduction in disease progression risk.
CELESTIMO is a confirmatory study intended to convert Lunsumio's accelerated third-line approval to full approval and secure a second-line or later indication.
Genentech, a member of the Roche Group, announced that the Phase III CELESTIMO study evaluating Lunsumio (mosunetuzumab-axgb) in combination with lenalidomide met its primary endpoint at the interim analysis in people with relapsed or refractory follicular lymphoma (搜索) (FL) who have received at least one prior line of treatment. The regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with Rituxan (rituximab) plus lenalidomide.
Overall survival data were immature at the time of the interim analysis. The safety profile of the Lunsumio and lenalidomide combination was consistent with the known profiles of the individual study medicines, with no new safety signals identified. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting.
A Confirmatory Trial With Regulatory Weight
CELESTIMO [NCT04712097] is a Phase III trial evaluating the efficacy and safety of Lunsumio in combination with lenalidomide versus rituximab plus lenalidomide in people with relapsed or refractory FL who have received at least one line of prior systemic therapy. It is a confirmatory study required to convert the accelerated approval/conditional marketing authorization of Lunsumio monotherapy for third-line or later (3L+) FL to full approval, as well as to secure an indication in second-line or later (2L+) FL.
The CELESTIMO population is broader than Lunsumio's approved indication: patients needed only one prior line of treatment to enroll, and the comparator arm used rituximab plus lenalidomide, a combination with a long track record in this setting. Beating that regimen on PFS in a randomized trial carries more regulatory weight than the single-arm response data that supported accelerated approval, and Roche will likely use these results to seek conversion to full approval and to expand the label to earlier lines. The question regulators and oncologists will ask is how large the PFS benefit was, a figure Roche has not yet released ahead of a conference presentation.
"The CELESTIMO results indicate that a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
A CD20xCD3 Bispecific in a Crowded Field
Lunsumio is a first-in-class CD20xCD3 T-cell-engaging bispecific antibody designed to target CD20 (搜索) on the surface of B cells and CD3 (搜索) on the surface of T cells. This dual-targeting activates and redirects a patient's existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. Lunsumio is part of Genentech's CD20xCD3 bispecific antibody program and is designed with the unique needs and preferences of patients in mind, offering the possibility of outpatient treatment and flexibility between intravenous and subcutaneous administration routes.
Lunsumio is already approved for people with 3L+ FL in 60 countries worldwide and has been used to treat over 3,800 patients. The U.S. Food and Drug Administration granted accelerated approval in December 2022 based on response rate alone in patients who had received at least two prior lines of therapy.
The competitive context makes the magnitude of the PFS benefit consequential. Epcoritamab in combination with lenalidomide and rituximab received FDA approval in November 2025 for relapsed or refractory follicular lymphoma (搜索), meaning bispecific antibody-based regimens are no longer a novel category in this disease. Mosunetuzumab is delivered subcutaneously in a fixed-duration course, a design that differs from some continuous-therapy approaches, but clinicians choosing between bispecific-based combinations will weigh the actual PFS curves, not just the mechanism. A narrow separation from the rituximab-lenalidomide arm would read differently than a substantial one when placed alongside data from competing regimens.
Broader Development Program
With the longest follow-up data of any bispecific antibody in lymphoma and a broad clinical development program spanning multiple disease settings, including both FL and diffuse large B-cell lymphoma (搜索) (DLBCL), Lunsumio is being investigated as a monotherapy and in combination with other medicines for B-cell non-Hodgkin lymphomas. The FDA recently accepted the supplemental Biologics License Application for Lunsumio in combination with Polivy (polatuzumab vedotin-piiq) for 2L+ DLBCL based on the SUNMO study, and results from CELESTIMO support continued expansion of Lunsumio and lenalidomide into earlier FL treatment, with the Phase III MorningLyte study ongoing in first-line FL.
Polivy is a first-in-class anti-CD79b (搜索) antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin lymphoma, making it a promising target for the development of new therapies. Polivy is being developed by Genentech using Pfizer ADC technology.
Disease Burden and Unmet Need
Follicular lymphoma (搜索) is the most common slow-growing (indolent) form of non-Hodgkin lymphoma, accounting for about one in five cases. It typically responds well to treatment but is often characterized by periods of remission and relapse. The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis. It is estimated that, in the United States, more than 15,000 new cases of FL will be diagnosed in 2026, and more than 110,000 people are diagnosed with FL each year worldwide.
Safety Considerations
Lunsumio and Lunsumio VELO carry boxed warnings for cytokine release syndrome (CRS), which is common during treatment and can be severe or life-threatening, and for neurologic problems, including serious and life-threatening events. Due to the risk of CRS, patients receive the drug on a step-up dosing schedule, with smaller step-up doses before higher doses during the first cycle of treatment. Other serious risks include serious infections that may lead to death, hemophagocytic lymphohistiocytosis (HLH), low blood cell counts, and tumor flare.
The most common side effects of Lunsumio include CRS, tiredness, rash, headache, fever, muscle pain, cough, itching, and numbness, tingling, or pain in the hands or feet. The most common side effects of Lunsumio VELO include injection site reactions, tiredness, rash, CRS, COVID-19, muscle and joint pain, and diarrhea.
The number that will define how this data moves the field is the hazard ratio for progression-free survival, and that is the figure worth waiting for before drawing conclusions about where mosunetuzumab lands in the treatment sequence.